Features of the lipid profile of the blood in comorbid patients with chronic obstructive pulmonary disease and arterial hypertension

Kovalenko O.M.,Rodionova V.V.

Main
Publications
Features of the lipid profile of the blood in comorbid patients with chronic obstructive pulmonary disease and arterial hypertension

October 11, 2018

857

Allergology and Pulmonology

Cardiology, Rheumatology

Therapy, General practice

Kovalenko O.M.

Rodionova V.V.

Specialities :

Allergology and Pulmonology

Cardiology, Rheumatology

Therapy, General practice

Resume

Objective — to investigate the lipid profile, its changes, depending on age, body mass index (BMI), smoking and features of chronic obstructive pulmonary disease (COPD) in comorbide patients with COPD and hypertension hypertension (AH). 86 patients were examined. In 1^st group there were 44 patients with COPD II—IV stages and AH I–II stages, in 2^nd group — 42 patients with AH І–ІІ stages.

Methods of research: determination of BMI, blood pressure, smoking status and evaluation of the degree of nicotine dependence, plasma levels of total cholesterol (TC), its fractions, triglycerides. In the 1^st group spirography examination (forced expiratory volume in 1 second (FEV₁), forced vital capacity (FVC) and their ratio — FEV₁/FVC), evaluation of dyspnea severity by mMRS, frequency of exacerbations during the year were performed.

Results and findings. Manifestations of dyslipidemia are more evident in patients with isolated AH than with COPD and AH. With aging in patients with a negative smoking status, the level of proatherogenic indicators of the lipid profile increases both in AH and in COPD and AH patients. Smoking in both groups contributes to the development of dyslipidemia regardless of age. In patients with AH, dyslipidemia mostly has a complex nature (IIb phenotype), and its severity increases with increasing body weight and the level of nicotine addiction. When combined with COPD and AH, dyslipidemia has the nature of hypercholesterolemia (IIa phenotype), it is detected and is an agedepended in patients with BMI >25 kg/m², its manifestations increase with an increase of bronchoobstuction. In patients with COPD and AH with severe bronchoobstuction, BMI and triglyceride levels decrease. With aging, levels of triglycerides as well as TC, very low-density lipoprotein cholesterol decrease, but there is no decrease in atherogenic coefficient, which indicates the steadiness of proatherogenic ratios of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in this category of patients.

O.M. Kovalenko, V.V. Rodionova

Key words: chronic obstructive pulmonary disease, hypertension, cardiovascular risk factors, dyslipidemia.

Published: 29.10.2018

References:

Basanets A.V., Dolinchuk L.V. (2017) Khronichne obstruktyvne zakhvoriuvannia lehen ta henetychna skhylnist. Dovkillia ta zdorovia, 1: 4–10.
Hashynova K.Iu. (2015) Zahostrennia KhOZL: faktory, shcho vplyvaiut na tryvalist hospitalizatsii. Med. perspekt., 20(1): 75–81.
Kovalenko V.M., Lutai M.I., Sirenko Yu.M., Sychov O.S. (red.) (2016) Sertsevo-sudynni zakhvoriuvannia: klasyfikatsiia, standarty diahnostyky ta likuvannia. MORION, Kyiv, 192 s.
Kovalenko V.N., Svischenko E.P. (red.) (2009) Arterialnaya gipertenziya u osobyih kategoriy bolnyih. MORION, Kiev, 376 s.
Konopkina L.I. (2016) Podhodyi k lecheniyu bolnyih hronicheskim obstruktivnyim zabolevaniem legkih v zavisimosti ot fenotipov. pulmonol. zhurn., 2: 56–57.
Agusti A., Calverley P.M., Celli B. et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators (2010) Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res., 11: 122.
Chen W., Thomas J., Sadatsafavi M., FitzGerald J.M. (2015) Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir. Med., 3(8): 631–639.
Decramer M., Janssens W. (2013) Chronic obstructive pulmonary disease and comorbidities. Lancet Respir. Med., 1(1): 73–83.
Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2018) The Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (http://www.goldcopd.org).
Maclay J.M., MacNee W. (2013) Assessment of cardiovascular comorbidity. Eur. Respir. Monogr., 59: 28–49.
Mancia G., Fagard R., Narkiewicz K. et al.; Task Force Members (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 31(7): 1281–357.
Rutten E., Wouters E. (2013) Malnutrition and obesity in COPD. Eur. Respir. Monogr., 59: 80–92.
World Health Organization (2018) The top 10 causes of death (http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death).
Yin H.L., Yin S.Q., Lin Q.Y. et al. (2017) Prevalence of comorbidities in chronic obstructive pulmonary disease patients: a meta-analysis. Medicine (Baltimore), 96(19): e6836.